×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Annexon Inc. (ANNX) NASDAQ

$7.81 0.93 (13.52%)

Market Cap: $612.06M

As of 03/27/24 04:00 PM EDT. Market closed.

(ANNX)

Annexon Inc. (ANNX)
NASDAQ

$7.81
0.93 (13.52%)

Market Cap: $612.06M

As of 03/27/24 04:00 PM EDT. Market closed.

Add to Portfolio

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration ... read more

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd). read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Address
.
PRICE CHART FOR ANNEXON INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$7.40
Previous Close
$6.88
Days Range
$7.16 - $8.39
52 week range
$1.57 - $8.40
Volume
5,321,097
Avg. Volume (30 days)
2,488,584
Market Cap
$612.06M
Dividend Yield
-
P/E
-
Shares Outstanding
78,369,099
Open
$7.40
Previous Close
$6.88
Days Range
$7.16 - $8.39
52 week range
$1.57 - $8.40
Volume
5,321,097
Avg. Volume (30 days)
2,488,584
Market Cap
$612.06M
Dividend Yield
-
P/E
-
Shares Outstanding
78,369,099
FINANCIAL STATEMENTS FOR ANNEXON INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ANNEXON INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 20, 2024 Sale$5.532,59314,33982,058Feb 21, 2024, 04:31 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 12, 2024 Sale$5.531,3497,46048,592Feb 14, 2024, 07:59 PM
Love DouglasPRESIDENT AND CEOFeb 12, 2024 Sale$5.545,78232,032196,121Feb 14, 2024, 07:56 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 12, 2024 Sale$5.541,80910,02245,651Feb 14, 2024, 07:54 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 12, 2024 Sale$5.541,81010,02736,075Feb 14, 2024, 07:52 PM
Yednock TedEVP & Chief Innovation OfficerDec 27, 2023 Option Exercise$1.6321,00034,17658,885Jan 23, 2024, 05:00 PM
Yednock TedEVP & Chief Innovation OfficerDec 27, 2023 Sale$4.5221,00094,96637,885Jan 23, 2024, 05:00 PM
Yednock TedEVP & Chief Innovation OfficerJul 11, 2023 Sale$3.841,0574,05537,885Jan 23, 2024, 05:00 PM
Overdorf MichaelEVP & Chief Business OfficerJul 11, 2023 Sale$3.849783,75245,802Jan 23, 2024, 04:58 PM
Lew JenniferEVP & Chief Financial OfficerJul 11, 2023 Sale$3.841,0574,05547,460Jan 23, 2024, 04:57 PM
Yednock TedEVP & Chief Innovation OfficerDec 27, 2023 Option Exercise$1.6321,00034,17621,000Dec 29, 2023, 04:12 PM
Yednock TedEVP & Chief Innovation OfficerDec 27, 2023 Sale$4.5221,00094,9660Dec 29, 2023, 04:12 PM
Satter Muneer ADirectorDec 26, 2023 Buy$2.88350,0001,008,0007,406,024Dec 28, 2023, 04:30 PM
Bain Capital Life Sciences Investors, LLC10% OwnerMay 25, 2023 Buy$2.13300,000639,7205,701,926May 30, 2023, 09:54 PM
Love DouglasPresident & CEOFeb 15, 2023 Sale$5.876,57138,564197,646Feb 17, 2023, 05:12 PM
Overdorf MichaelEVP & Chief Business OfficerFeb 14, 2023 Sale$6.3014490727,805Feb 15, 2023, 07:00 PM
Overdorf MichaelEVP & Chief Business OfficerFeb 13, 2023 Sale$6.301,5019,46127,949Feb 15, 2023, 07:00 PM
Lew JenniferEVP & Chief Financial OfficerFeb 14, 2023 Sale$6.301661,04629,542Feb 15, 2023, 06:59 PM
Lew JenniferEVP & Chief Financial OfficerFeb 13, 2023 Sale$6.311,74210,98929,708Feb 15, 2023, 06:59 PM
Satter Muneer ADirectorFeb 10, 2023 Buy$6.802,647,05817,999,9957,056,024Feb 14, 2023, 04:31 PM
Satter Muneer ADirectorJul 07, 2022 Buy$3.842,453,9889,423,3144,408,966Jul 11, 2022, 08:42 PM
Love DouglasPresident & CEOApr 14, 2022 Buy$2.4560,000146,814200,942Apr 18, 2022, 07:04 PM
Love DouglasPresident & CEONov 11, 2021 Option Exercise$1.54100,942155,503100,942Nov 15, 2021, 06:05 PM
Love DouglasPresident & CEOSep 16, 2021 Option Exercise$1.417,50010,5727,500Sep 20, 2021, 05:46 PM
Love DouglasPresident & CEOSep 16, 2021 Sale$22.057,500165,3410Sep 20, 2021, 05:46 PM
Yednock TedEVP & Chief Scientific OfficerSep 13, 2021 Option Exercise$1.6816,19027,22516,190Sep 15, 2021, 06:35 PM
Yednock TedEVP & Chief Scientific OfficerSep 13, 2021 Sale$20.0016,190323,8600Sep 15, 2021, 06:35 PM
Lew JenniferEVP & Chief Financial OfficerSep 13, 2021 Option Exercise$7.493,50026,2105,500Sep 15, 2021, 06:35 PM
Lew JenniferEVP & Chief Financial OfficerSep 13, 2021 Sale$20.013,50070,0342,000Sep 15, 2021, 06:35 PM
Yednock TedEVP & Chief Scientific OfficerJun 03, 2021 Option Exercise$1.4115,00021,14415,000Jun 07, 2021, 04:47 PM
Yednock TedEVP & Chief Scientific OfficerJun 03, 2021 Sale$21.4915,000322,3252,184Jun 07, 2021, 04:47 PM
Love DouglasPresident & CEOApr 01, 2021 Option Exercise$1.41500705500Apr 02, 2021, 12:31 PM
Love DouglasPresident & CEOMar 31, 2021 Option Exercise$1.417,10210,0117,102Apr 02, 2021, 12:31 PM
Love DouglasPresident & CEOApr 01, 2021 Sale$28.0850014,041300Apr 02, 2021, 12:31 PM
Love DouglasPresident & CEOMar 31, 2021 Sale$28.117,102199,6210Apr 02, 2021, 12:31 PM
Love DouglasPresident & CEOMar 29, 2021 Option Exercise$1.413,7505,2863,750Mar 31, 2021, 04:04 PM
Love DouglasPresident & CEOMar 30, 2021 Option Exercise$1.413,7505,2863,750Mar 31, 2021, 04:04 PM
Love DouglasPresident & CEOMar 29, 2021 Sale$25.423,75095,334900Mar 31, 2021, 04:04 PM
Love DouglasPresident & CEOMar 30, 2021 Sale$24.523,75091,9661,850Mar 31, 2021, 04:04 PM
Yednock TedEVP & Chief Scientific OfficerMar 25, 2021 Option Exercise$1.6816,17527,14816,175Mar 29, 2021, 05:10 PM
Yednock TedEVP & Chief Scientific OfficerMar 25, 2021 Sale$28.8016,175465,7705,917Mar 29, 2021, 05:10 PM
Keswani SanjayEVP & Chief Medical OfficerMar 24, 2021 Option Exercise$7.493,99529,9173,995Mar 26, 2021, 05:52 PM
Keswani SanjayEVP & Chief Medical OfficerMar 24, 2021 Sale$30.173,995120,5120Mar 26, 2021, 05:52 PM
Lew JenniferEVP & Chief Financial OfficerMar 23, 2021 Option Exercise$7.495,00037,4437,000Mar 25, 2021, 07:31 PM
Lew JenniferEVP & Chief Financial OfficerMar 23, 2021 Sale$28.445,000142,1765,600Mar 25, 2021, 07:31 PM
Clarus Lifesciences III, L.P.10% OwnerJul 28, 2020 Buy$17.00200,0003,400,0002,730,635Jul 30, 2020, 08:00 PM
Bain Capital Life Sciences Investors, LLC10% OwnerJul 28, 2020 Buy$17.00400,0006,800,0003,241,628Jul 28, 2020, 04:45 PM
Lew JenniferEVP & Chief Financial OfficerJul 28, 2020 Buy$17.002,00034,0002,000Jul 28, 2020, 04:18 PM
Satter Muneer ADirectorJul 28, 2020 Buy$17.00200,0003,400,0001,954,978Jul 28, 2020, 04:17 PM
Flynn James E10% OwnerJul 28, 2020 Buy$17.00350,0005,950,000808,914Jul 28, 2020, 12:54 PM
Flynn James E10% OwnerJul 28, 2020 Buy$17.00350,0005,950,000808,914Jul 28, 2020, 12:54 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Lew JenniferEVP & CHIEF FINANCIAL OFFICER02/20/202414,339
Overdorf MichaelEVP & CHIEF BUSINESS OFFICER02/12/20247,460
Love DouglasPRESIDENT AND CEO02/12/202432,032
Lew JenniferEVP & CHIEF FINANCIAL OFFICER02/12/202410,022
Yednock TedEVP & CHIEF INNOVATION OFFICER02/12/202410,027
Yednock TedEVP & Chief Innovation Officer12/27/202334,176
Yednock TedEVP & Chief Innovation Officer12/27/202394,966
Yednock TedEVP & Chief Innovation Officer07/11/20234,055
Overdorf MichaelEVP & Chief Business Officer07/11/20233,752
Lew JenniferEVP & Chief Financial Officer07/11/20234,055
Yednock TedEVP & Chief Innovation Officer12/27/202334,176
Yednock TedEVP & Chief Innovation Officer12/27/202394,966
Satter Muneer ADirector12/26/20231,008,000
Bain Capital Life Sciences Investors, LLC10% Owner05/25/2023639,720
Love DouglasPresident & CEO02/15/202338,564
Overdorf MichaelEVP & Chief Business Officer02/14/2023907
Overdorf MichaelEVP & Chief Business Officer02/13/20239,461
Lew JenniferEVP & Chief Financial Officer02/14/20231,046
Lew JenniferEVP & Chief Financial Officer02/13/202310,989
Satter Muneer ADirector02/10/202317,999,995
Satter Muneer ADirector07/07/20229,423,314
Love DouglasPresident & CEO04/14/2022146,814
Love DouglasPresident & CEO11/11/2021155,503
Love DouglasPresident & CEO09/16/202110,572
Love DouglasPresident & CEO09/16/2021165,341
Yednock TedEVP & Chief Scientific Officer09/13/202127,225
Yednock TedEVP & Chief Scientific Officer09/13/2021323,860
Lew JenniferEVP & Chief Financial Officer09/13/202126,210
Lew JenniferEVP & Chief Financial Officer09/13/202170,034
Yednock TedEVP & Chief Scientific Officer06/03/202121,144
Yednock TedEVP & Chief Scientific Officer06/03/2021322,325
Love DouglasPresident & CEO04/01/2021705
Love DouglasPresident & CEO03/31/202110,011
Love DouglasPresident & CEO04/01/202114,041
Love DouglasPresident & CEO03/31/2021199,621
Love DouglasPresident & CEO03/29/20215,286
Love DouglasPresident & CEO03/30/20215,286
Love DouglasPresident & CEO03/29/202195,334
Love DouglasPresident & CEO03/30/202191,966
Yednock TedEVP & Chief Scientific Officer03/25/202127,148
Yednock TedEVP & Chief Scientific Officer03/25/2021465,770
Keswani SanjayEVP & Chief Medical Officer03/24/202129,917
Keswani SanjayEVP & Chief Medical Officer03/24/2021120,512
Lew JenniferEVP & Chief Financial Officer03/23/202137,443
Lew JenniferEVP & Chief Financial Officer03/23/2021142,176
Clarus Lifesciences III, L.P.10% Owner07/28/20203,400,000
Bain Capital Life Sciences Investors, LLC10% Owner07/28/20206,800,000
Lew JenniferEVP & Chief Financial Officer07/28/202034,000
Satter Muneer ADirector07/28/20203,400,000
Flynn James E10% Owner07/28/20205,950,000
Flynn James E10% Owner07/28/20205,950,000
Load More Insider Transactions
FUNDS WITH A POSITION IN ANNEXON INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
ADAGE CAPITAL PARTNERS GP, L.L.C.4,999,9750.05%112.77%Other
BLACKROCK INC.3,318,5790.00038%-2.62%Other
GEODE CAPITAL MANAGEMENT, LLC922,2320.00044%4.84%Other
BLACKSTONE INC.910,4940.009%ExitedOther
UBS OCONNOR LLC692,9280.23%26.16%Value
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)583,9130.05%No changeOther
RENAISSANCE TECHNOLOGIES LLC484,2000.0034%-13.74%Other
UBS OCONNOR LLC300,000 (Call)0.00056%ExitedValue
DRIEHAUS CAPITAL MANAGEMENT LLC258,3140.00251%No changeGrowth
BALYASNY ASSET MANAGEMENT L.P.10,1070.00009%NewEvent Driven
CHANGE IN SHARES OUTSTANDING FOR ANNEXON INC
STOCK BUYBACKS FOR ANNEXON INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
3.85%
1Q
12/31/2023
06/30/2023
4.01%
2Q
12/31/2023
03/31/2023
5.95%
3Q
12/31/2023
12/31/2022
43.12%
4Q
12/31/2023
09/30/2022
13.97%
5Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
3.85%
1Q
06/30/2023
4.01%
2Q
03/31/2023
5.95%
3Q
12/31/2022
43.12%
4Q
09/30/2022
13.97%
5Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ANNEXON INC
LOADING...